Faricimab efficacy in a poorly responsive case of Polypoidal Choroidal Vasculopathy (PCV): A case report
PurposeTo evaluate anatomical and functional outcomes of Faricimab therapy on a case of polypoidal choroidal vasculopathy (PCV) refractory to previous treatments.Major findingsA 56-year-old patient with PCV presenting with a large pigment epithelial detachment (PED) showed best-corrected visual acuity (BCVA) improvement, subretinal fluid (SRF) reduction and PED height reduction at 2 months follow up after a loading phase of 4 monthly Faricimab injections. The patient had previously undergone Aflibercept, Brolucizumab and photodynamic therapy (PDT) treatments with a suboptimal response.ConclusionDespite Faricimab proving itself as an efficient alternative in a case of PCV poorly responsive to previous treatments, definite evidence still needs to be confirmed in larger studies.
Authors
- Clara Rizzo (ORCID: https://orcid.org/0000-0002-5156-5314)
- Raphael Kilian (ORCID: https://orcid.org/0000-0001-7410-8805)
- Maria Cristina Savastano (ORCID: https://orcid.org/0000-0003-1397-4333)
- Stanislao Rizzo (ORCID: https://orcid.org/0000-0001-6302-063X)
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Verona (IT)
- University of Ferrara (IT)
- Agostino Gemelli University Polyclinic (IT)
- Neuroscience Institute (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- European Journal of Ophthalmology
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1177/11206721241310629
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71